RomanBabakin
- Sanofi (NASDAQ:SNY) is up ~3% in Monday afternoon trading as it stands to benefit from positive data released earlier in the day on Alnylam Pharmaceuticals’ (ALNY) Amvuttra (vutrisiran)
- The data was on the drug in treating ATTR amyloidosis with cardiomyopathy. The therapoy was already approved for polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
- Sanofi (SNY) receives tiered royalties of 15%-30% on Amvuttra sales, according to Citi analyst Peter Vernault, who also called the drug an “underappreciated multi-billion dollar royalty stream.”